Amgen Inc. (NASDAQ:AMGN) Shares Bought by Daymark Wealth Partners LLC

Daymark Wealth Partners LLC grew its stake in Amgen Inc. (NASDAQ:AMGN - Free Report) by 0.9% in the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 241,022 shares of the medical research company's stock after buying an additional 2,166 shares during the quarter. Amgen accounts for about 2.6% of Daymark Wealth Partners LLC's investment portfolio, making the stock its 6th biggest holding. Daymark Wealth Partners LLC's holdings in Amgen were worth $75,090,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds also recently made changes to their positions in AMGN. Centricity Wealth Management LLC acquired a new position in shares of Amgen in the fourth quarter valued at approximately $25,000. Pinney & Scofield Inc. bought a new stake in shares of Amgen in the fourth quarter worth $26,000. Ritter Daniher Financial Advisory LLC DE lifted its position in shares of Amgen by 66.2% in the fourth quarter. Ritter Daniher Financial Advisory LLC DE now owns 128 shares of the medical research company's stock worth $33,000 after purchasing an additional 51 shares in the last quarter. Synergy Investment Management LLC bought a new stake in shares of Amgen in the fourth quarter worth $34,000. Finally, Atala Financial Inc bought a new stake in shares of Amgen in the fourth quarter worth $34,000. Institutional investors and hedge funds own 76.50% of the company's stock.

Amgen Price Performance

Shares of AMGN opened at $290.33 on Monday. The firm has a market capitalization of $156.11 billion, a PE ratio of 38.45, a PEG ratio of 2.63 and a beta of 0.51. The company's 50-day moving average is $281.57 and its 200-day moving average is $285.39. Amgen Inc. has a fifty-two week low of $253.30 and a fifty-two week high of $346.85. The company has a debt-to-equity ratio of 9.62, a current ratio of 1.26 and a quick ratio of 0.95.

Amgen (NASDAQ:AMGN - Get Free Report) last issued its quarterly earnings data on Thursday, May 1st. The medical research company reported $4.90 earnings per share for the quarter, beating the consensus estimate of $4.18 by $0.72. The company had revenue of $8.15 billion for the quarter, compared to analyst estimates of $8.05 billion. Amgen had a net margin of 12.24% and a return on equity of 176.32%. The company's revenue was up 9.4% on a year-over-year basis. During the same period in the prior year, the firm earned $3.96 earnings per share. Equities analysts forecast that Amgen Inc. will post 20.62 EPS for the current year.

Insider Activity at Amgen

In related news, SVP Rachna Khosla sold 1,500 shares of the company's stock in a transaction dated Thursday, June 5th. The shares were sold at an average price of $289.68, for a total value of $434,520.00. Following the transaction, the senior vice president now directly owns 8,162 shares in the company, valued at approximately $2,364,368.16. This represents a 15.52% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. 0.76% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

A number of analysts have recently commented on the stock. Cantor Fitzgerald assumed coverage on shares of Amgen in a research report on Tuesday, April 22nd. They issued a "neutral" rating and a $305.00 price objective on the stock. Piper Sandler cut their price objective on shares of Amgen from $329.00 to $328.00 and set an "overweight" rating on the stock in a research report on Friday, May 16th. UBS Group reissued a "neutral" rating and issued a $315.00 price objective (down previously from $319.00) on shares of Amgen in a research report on Friday, May 2nd. Johnson Rice set a $294.00 price objective on shares of Amgen in a research report on Wednesday, March 5th. Finally, Bank of America boosted their price objective on shares of Amgen from $275.00 to $294.00 and gave the stock an "underperform" rating in a research report on Wednesday, March 5th. Two research analysts have rated the stock with a sell rating, twelve have given a hold rating, nine have assigned a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of "Hold" and a consensus price target of $309.22.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.